New antibiotic combo takes on deadly hospital pneumonia
NCT ID NCT07327619
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests a new antibiotic combination (meropenem and pralurbactam) against an existing one (ceftazidime and avibactam) for treating hospital-acquired and ventilator-associated bacterial pneumonia. About 420 adults will participate, and the main goal is to see if the new drug is at least as good at preventing death within 14 days. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Meropenem and pralurbactam (antibiotic combination)
- What this could lead to
- If it works, this could provide a new treatment option for serious hospital-acquired pneumonia, potentially saving lives.
- What could go wrong
- This is a phase 3 trial, but it's testing non-inferiority, not superiority, so the new drug may not be better than existing options. Side effects and antibiotic resistance are possible risks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan University Of Medicine General Hospital
RECRUITINGHuaihua, Hunan, 418000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.